Insmed (INSM) – Investment Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Insmed (NASDAQ: INSM) in the last few weeks:

• 11/2/2026 – Insmed had its “buy” rating reaffirmed by Benchmark.
• 11/2/2026 – Insmed had its price target lowered by Guggenheim from $205.00 to $201.00. They now have a “buy” rating on the stock.
• 10/29/2026 – Insmed was given a new $195.00 price target by Stifel Nicolaus.
• 10/29/2026 – Insmed was given a new $154.00 price target by Mizuho.
• 10/27/2026 – Insmed had its “buy” rating reaffirmed by HC Wainwright.
• 10/21/2026 – Insmed had its price target lowered by Morgan Stanley from $218.00 to $213.00. They now have an “overweight” rating on the stock.
• 10/20/2026 – Insmed was given a new $173.00 price target by Raymond James Financial.
• 10/15/2026 – Insmed had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/12/2026 – Insmed had its “buy” rating reaffirmed by Bank of America. They now have a $207.00 price target on the stock.
• 10/12/2026 – Insmed was downgraded by Wolfe Research from “outperform” to “peer perform”.
• 10/12/2026 – Insmed had its “buy” rating reaffirmed by HC Wainwright. They now have a $220.00 price target on the stock.
• 10/8/2026 – Insmed had its “buy” rating reaffirmed by UBS Group.
• 10/6/2026 – Insmed had its “outperform” rating reaffirmed by BMO Capital Markets.
• 9/30/2026 – Insmed had its price target lowered by Barclays from $237.00 to $207.00. They now have an “overweight” rating on the stock.
• 9/24/2026 – Insmed is now covered by The Goldman Sachs Group. They set a “buy” rating and a $188.00 price target on the stock.
• 9/24/2026 – Insmed is now covered by The Goldman Sachs Group. They set a “buy” rating and a $188.00 price target on the stock.
• 9/15/2026 – Insmed had its “buy” rating reaffirmed by Roth Capital. They now have a $198.00 price target on the stock, down from $212.00.

Insider Activity at Insmed

In related news, COO Roger Adsett sold 239,850 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $133.27, for a total value of $31,964,809.50. Following the completion of the transaction, the chief operating officer owned 98,744 shares of the company’s stock, valued at $13,159,612.88. This represents a 70.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director David R. Brennan sold 25,000 shares of Insmed stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total value of $3,100,000.00. Following the transaction, the director directly owned 39,238 shares of the company’s stock, valued at approximately $4,865,512. The trade was a 38.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 2.10% of the company’s stock.

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company concentrates on conditions with significant unmet medical needs, particularly in pulmonary and infectious diseases.

Insmed’s lead commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy used in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.